Bad news by an advisory panel to the FDA was the specific reason for the shares crashing. That panel is not the final word. The FDA will make the final ruling in February. The company has quintupled the upgrades for drug production 2012 over 2011. CFS patients are in an uproar over the negative news, wanting to voice their collective opinion that many benefit from drug treatment. No other drug is near CFS drug approval. If the FDA chooses to conditionally approve the Hemispherx drug, the share price will move to $3 this year.
NOTE: I am not responsible for any decision you make, whether it be buy, hold, sell or sell short.